Cargando…
Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remai...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211709/ https://www.ncbi.nlm.nih.gov/pubmed/34140527 http://dx.doi.org/10.1038/s41467-021-24087-8 |
_version_ | 1783709523636125696 |
---|---|
author | Zhao, Li Wang, Shumei Xu, Meng He, Yang Zhang, Xiaowei Xiong, Ying Sun, Hong Ding, Haibo Geng, Wenqing Shang, Hong Liang, Guoxin |
author_facet | Zhao, Li Wang, Shumei Xu, Meng He, Yang Zhang, Xiaowei Xiong, Ying Sun, Hong Ding, Haibo Geng, Wenqing Shang, Hong Liang, Guoxin |
author_sort | Zhao, Li |
collection | PubMed |
description | The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remains elusive. Here, we report that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages. LAPTM5 transports HIV-1 envelope glycoproteins to lysosomes for degradation, thereby inhibiting virion infectivity. Vpr counteracts the restrictive effects of LAPTM5 by triggering its degradation via DCAF1. In the absence of Vpr, the silencing of LAPTM5 precisely phenocopied the effect of Vpr on HIV-1 infection. In contrast, Vpr did not enhance HIV-1 infection in the absence of LAPTM5. Moreover, LAPTM5 was highly expressed in macrophages but not in CD4(+) T lymphocytes. Re-expressing LAPTM5 reconstituted the Vpr-dependent promotion of HIV-1 infection in primary CD4(+) T cells, as observed in macrophages. Herein, we demonstrate the molecular mechanism used by Vpr to overcome LAPTM5 restriction in macrophages, providing a potential strategy for anti-HIV/AIDS therapeutics. |
format | Online Article Text |
id | pubmed-8211709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82117092021-07-01 Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages Zhao, Li Wang, Shumei Xu, Meng He, Yang Zhang, Xiaowei Xiong, Ying Sun, Hong Ding, Haibo Geng, Wenqing Shang, Hong Liang, Guoxin Nat Commun Article The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remains elusive. Here, we report that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages. LAPTM5 transports HIV-1 envelope glycoproteins to lysosomes for degradation, thereby inhibiting virion infectivity. Vpr counteracts the restrictive effects of LAPTM5 by triggering its degradation via DCAF1. In the absence of Vpr, the silencing of LAPTM5 precisely phenocopied the effect of Vpr on HIV-1 infection. In contrast, Vpr did not enhance HIV-1 infection in the absence of LAPTM5. Moreover, LAPTM5 was highly expressed in macrophages but not in CD4(+) T lymphocytes. Re-expressing LAPTM5 reconstituted the Vpr-dependent promotion of HIV-1 infection in primary CD4(+) T cells, as observed in macrophages. Herein, we demonstrate the molecular mechanism used by Vpr to overcome LAPTM5 restriction in macrophages, providing a potential strategy for anti-HIV/AIDS therapeutics. Nature Publishing Group UK 2021-06-17 /pmc/articles/PMC8211709/ /pubmed/34140527 http://dx.doi.org/10.1038/s41467-021-24087-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhao, Li Wang, Shumei Xu, Meng He, Yang Zhang, Xiaowei Xiong, Ying Sun, Hong Ding, Haibo Geng, Wenqing Shang, Hong Liang, Guoxin Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title | Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title_full | Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title_fullStr | Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title_full_unstemmed | Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title_short | Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages |
title_sort | vpr counteracts the restriction of laptm5 to promote hiv-1 infection in macrophages |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211709/ https://www.ncbi.nlm.nih.gov/pubmed/34140527 http://dx.doi.org/10.1038/s41467-021-24087-8 |
work_keys_str_mv | AT zhaoli vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT wangshumei vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT xumeng vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT heyang vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT zhangxiaowei vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT xiongying vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT sunhong vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT dinghaibo vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT gengwenqing vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT shanghong vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages AT liangguoxin vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages |